Look at the stock price - Anonymous employee Modivcare Employee Review

ModivCare stands as a cautionary tale in what happens when a company in a mission-critical industry like healthcare logistics fails to confront its systemic issues. The organization is mired in lawsuits, internal disarray, and a staggering erosion of investor confidence — reflected in its precipitous stock price collapse. But rather than course-correct, ModivCare’s leadership appears to be doubling down on failed strategies, throwing money and personnel at deeply broken systems without addressing root causes. At its core, ModivCare suffers from a complete lack of operational maturity. Its platform — critical to coordinating millions of non-emergency medical transportation rides — is deeply flawed. Billing is consistently inaccurate, frustrating partners, drivers, and patients alike. The result? Widespread distrust and administrative nightmares across the entire service ecosystem. Perhaps most damning is management’s response. Despite mounting evidence of systemic failure, the executive team continues to apply superficial solutions to deeply entrenched problems. Their preferred strategy — overspending on headcount and vendor contracts — has done little more than add complexity to an already disorganized environment. There is no coherent product roadmap, no unified vision, and no willingness to admit that the foundation is cracked. The result is a patchwork of quick fixes rather than long-term transformation. The legal landscape surrounding ModivCare is equally troubling. The company has faced class-action lawsuits and compliance challenges — all while investor confidence has nosedived. The stock price reflects this reality: a stark vote of no confidence from the market. What once held potential as a disruptive force in healthcare coordination is now viewed as a liability. ModivCare doesn’t need more consultants or a bloated org chart. It needs a reckoning. A total overhaul of leadership priorities, technology strategy, and customer engagement models. Until then, the company will remain an example of what happens when denial meets dysfunction — and the costs will continue to be borne by patients, providers, and shareholders alike.